Welcome to IntegraGen's News and Events page. Here you will find current and archived press releases, listings of upcoming events, and news coverage about the company and some of its projects and initiatives.

Contact us if you would like more information about IntegraGen and our efforts.

IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool for oncology sequencing data interpretation and reporting

IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…)  » 

COVID-19 update: IntegraGen remains committed to meeting our customers needs

Dear IntegraGen partner and customer,

We value your well-being and understand that the entire community is impacted by the novel coronavirus (COVID-19) outbreak. This is why we are committed to providing consistent and timely support so your important work is not interrupted.

IntegraGen is closely monitoring guidance from health authorities (…)  » 

Press release on General Assembly voting results

integragen

The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.

At the end of the Combined General Meeting, (…)  » 

IntegraGen Reports 2018 Annual Results

integragen

IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.

Click here to view press release.

 

 

IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked  diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

(…)  »